Compare Eli Lilly And Co (LLY) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Eli Lilly And Co trades at $1,175.8 (market cap $1.04T), while Vanguard Total Stock Market Index Fund ETF trades at $382.14 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 2.2× Eli Lilly And Co's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| LLY | VTI | |
|---|---|---|
Market Cap | $1.04T | $2.30T |
Volume | 3,064,878 | 2,982,924 |
Sector | Health | — |
52-Week High | $1.28K | $384.30 |
52-Week Low | $799.57 | $311.68 |
Typical Hold Time | 93 Days | 131 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
VTI trades at $381.82, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest and broad diversification across the U.S. stock market. Recent news highlights its long-term growth potential and cost efficiency, with a dividend scheduled for September 2026.
The outlook for VTI remains positive due to its low-cost structure and exposure to the entire U.S. equity market. Risks include concentration in top holdings and market volatility, but its historical performance supports a solid foundation for long-term investors seeking diversified growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
